Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AT-100 Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

NCT02932332
View directory record Official record
Conditions
Cancer
Interventions
High-flow Oxygen, Low-flow Oxygen, High-flow Air, Low-flow Air
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 25, 2026, 10:41 PM EDT
Recruiting Phase 3 Interventional

Hyperbaric Oxygen Treatment for Veterans With Traumatic Brain Injury

NCT06581003
View directory record Official record
Conditions
Traumatic Brain Injury, Military Operations
Interventions
Oxygen 99.7 %, Oxygen 21 %
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cranial Electrotherapy Stimulation: Piloting a Road to PTSD Prevention in First Responders

NCT06203717
View directory record Official record
Conditions
Adults, Firefighters
Interventions
Alpha-Stim AID cranial electrotherapy stimulation
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 56 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Terminated Phase 1 Interventional

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

NCT02630043
View directory record Official record
Conditions
Neuroblastoma
Interventions
Tolcapone, Oxaliplatin
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
0 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 25, 2026, 10:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab, Acalabrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

NCT02511431
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 25, 2026, 10:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of Hormones on Noninvasive Transcranial Stimulation

NCT07635017
View directory record Official record
Conditions
Cortical Excitability, Healthy, TMS, Menstrual Cycle, Menopause
Interventions
Transcranial Electrical Stimulation, Transcranial Magnetic Stimulation, TES + TMS
Device
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Completed No phase listed Observational

Removing Fluid Above Breathing Tubes in the Operating Room

NCT01110109
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Oct 25, 2026, 10:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b
Radiation · Drug · Biological
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Active, not recruiting Not applicable Interventional

Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

NCT02429570
View directory record Official record
Conditions
Recurrent Brain Metastases, Progressive Brain Metastases
Interventions
Meclofenamate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
7
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

NCT02283177
View directory record Official record
Conditions
Newly Diagnosed AML With FLT3 Activating Mutations
Interventions
crenolanib, cytarabine, daunorubicin, idarubicin
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Duarte, California • Iowa City, Iowa • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 25, 2026, 10:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

NCT05481151
View directory record Official record
Conditions
Polycythemia Vera
Interventions
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Jacksonville, Florida • Fort Wayne, Indiana • Westwood, Kansas + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 25, 2026, 10:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Menstrual Cycle TMS Plasticity Pilot

NCT07180654
View directory record Official record
Conditions
Cortical Activation
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Recruiting Early Phase 1 Interventional

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

NCT06906939
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
repetetive transcranial magnetic stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 10:41 PM EDT
Not listed No phase listed Observational

Ventilatory Parameters in Predicting Outcomes in ARDS Patients

NCT06400095
View directory record Official record
Conditions
ARDS, Mechanical Power
Interventions
Poccl, Time constant, driving pressure
Diagnostic Test
Lead sponsor
CentraCare
Other
Eligibility
19 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Saint Cloud, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 10:41 PM EDT
Terminated Not applicable Interventional Results available

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

NCT04025021
View directory record Official record
Conditions
Human Milk, Neonate, Breast Milk
Interventions
Targeted Fortification, The Miris Human Milk Analyzer
Dietary Supplement · Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
Up to 6 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 25, 2026, 10:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Personalized Moderate Intensity Exercise Training Combined With High Intensity Interval

NCT03568214
View directory record Official record
Conditions
Exercise, Metabolic Syndrome
Interventions
Exercise
Other
Lead sponsor
Western Colorado University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 25, 2026, 10:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

NCT05925608
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization
Combination Product · Diagnostic Test
Lead sponsor
BioCardia, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neuroimaging Biomarkers for Predicting rTMS Response in OCD

NCT04286126
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Active bilateral DMPFC, Active right-sided OFC
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 25, 2026, 10:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

NCT02311582
View directory record Official record
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 25, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 10:41 PM EDT